1800300-79-1

Basic information

• Product Name: methyl (2R)-2-amino-3-methoxypropanoate hydrochloride
• CAS NO: 1800300-79-1
• Molecular Weight: 169.608
• Mol File: 1800300-79-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: methyl (2R)-2-amino-3-methoxypropanoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (2R)-2-amino-3-methoxypropanoate hydrochloride(1800300-79-1)
• EPA Substance Registry System: methyl (2R)-2-amino-3-methoxypropanoate hydrochloride(1800300-79-1)

Safety Data

• Hazardous Substances Data: 1800300-79-1(Hazardous Substances Data)

Usage

General Description

Methyl (2R)-2-amino-3-methoxypropanoate hydrochloride, also known as L-methionine methyl ester hydrochloride, is a chemical compound used in the synthesis of pharmaceuticals and biochemicals. It is the methyl ester of L-methionine, an essential amino acid that is important for protein synthesis and is a precursor for the synthesis of other amino acids and important biomolecules. The hydrochloride salt form of this compound is commonly used for research purposes and as a laboratory reagent. It is a white to off-white crystalline powder that is soluble in water and has a molecular weight of 195.65 g/mol. The compound is typically stored in a cool, dry place and handled with appropriate safety precautions due to its potential for skin and eye irritation.

Upstream product

• 19794-53-7 3-methoxy-2-aminopropionic acid 
• 79-20-9 acetic acid methyl ester 
• 67-56-1 methanol 
• 4219-94-7 DL-3-methoxy-alanine 
• 134167-07-0 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-methoxypropanoate 
• 86118-11-8 D-o-methylserine 
• 86123-95-7 (R)-2-((tert-butoxycarbonyl)amino)-3-methoxypropionic acid 

Downstream Products

• 862372-14-3 methyl (R)-2-(tert-butoxycarbonylamino)-3-methoxypropanoate 
• 134167-07-0 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-methoxypropanoate 

Relevant articles and documents

Triazole-containing and cyclic derivative inhibitor Preparation method and application thereof

The invention relates to a triazolyl-containing and cyclic derivative inhibitor as well as a preparation method and application thereof. , The present invention relates to a compound represented by general formula (I), a preparation method and a pharmaceutical composition thereof, and a use thereof as NK inhibitor in treatment of related diseases such as depression, anxiety, schizophrenia and sex hormone dependence, and the like, wherein each substituent in the general formula (I) is the same as defined in the description.

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits

Subunit-selective proteasome inhibitors are valuable tools to assess the biological and medicinal relevance of individual proteasome active sites. Whereas the inhibitors for the β1c, β1i, β5c, and β5i subunits exploit the differences in the substrate-binding channels identified by X-ray crystallography, compounds selectively targeting β2c or β2i could not yet be rationally designed because of the high structural similarity of these two subunits. Here, we report the development, chemical synthesis, and biological screening of a compound library that led to the identification of the β2c- and β2i-selective compounds LU-002c (4; IC50 β2c: 8 nM, IC50 β2i/β2c: 40-fold) and LU-002i (5; IC50 β2i: 220 nM, IC50 β2c/β2i: 45-fold), respectively. Co-crystal structures with β2 humanized yeast proteasomes visualize protein-ligand interactions crucial for subunit specificity. Altogether, organic syntheses, activity-based protein profiling, yeast mutagenesis, and structural biology allowed us to decipher significant differences of β2 substrate-binding channels and to complete the set of subunit-selective proteasome inhibitors.

Preparation method for lacosamide

The invention provides a preparation method for lacosamide. According to the invention, easily available Boc-serine (a compound I) is used as a starting material for preparation of lacosamide, and the quality of prepared lacosamide is identical to the quality of an original drug. The preparation method provided by the invention uses easily available raw materials, does not need expensive iodomethane or severely toxic dimethyl sulfate, and is high in product purity and yield and low in toxicity and pollution, and requirements of reaction conditions on equipment are not high; thus, the method is suitable for industrial production.